PI3K/Akt/mTOR · target hub
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta (p110δ)
PIK3CD encodes the class I PI3K p110δ catalytic subunit, typically assembled with p85α/β or p55γ regulatory partners; it is enriched in lymphoid and myeloid compartments and couples BCR, Fc receptors, and many immune receptors to PIP3 generation. PI3Kδ-selective inhibitors are central in hematologic malignancy and immuno-inflammatory pharmacology—solid-tumor dependency must be validated per model.
| Type / example | Domain / context (brief) |
|---|---|
| E1021K 等（文献报道） | Kinase-proximal GOF reports (disease-context dependent) |
| CN / expression | Copy/expression shifts in lymphoid/leukemia research contexts |
| WT + BCR / FcR 轴 | WT p110δ amplifying BCR/FcR signaling in standard immune models |
| 种属差异 | Species differences in immune PI3Kδ pharmacology—annotate organism |
p110δ is enriched in hematopoietic/immune lineages—annotate gain-of-function lesions and copy changes with flow, sequencing, and clinical resources (COSMIC, ClinVar, literature).
Examples mirror common hematologic malignancy and immuno-pharmacology models—solid-tumor PIK3CD dependence must be validated per system; mind human vs murine immune differences.
PBMCs/primary B cells require ethics documentation—record donor status and stimulant lots for blood assays.
PI3Kδ inhibitor translation demands infection-risk and immunosuppression monitoring—do not extrapolate murine dosing directly to human PBMC assays.
Adds PIK3CD keyword bias atop the PI3K/Akt/mTOR antibody pool—if sparse, use presets above or global search.
This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.
Last reviewed: 2026-05-03
See the PI3K/Akt/mTOR hub for neighboring nodes and assay guidance—cross-check MAPK, RTK, metabolism, and autophagy pages as needed.